187 related articles for article (PubMed ID: 15609297)
1. Use of multiple biomarkers for a molecular diagnosis of prostate cancer.
Landers KA; Burger MJ; Tebay MA; Purdie DM; Scells B; Samaratunga H; Lavin MF; Gardiner RA
Int J Cancer; 2005 May; 114(6):950-6. PubMed ID: 15609297
[TBL] [Abstract][Full Text] [Related]
2. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
[TBL] [Abstract][Full Text] [Related]
3. Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis.
Klecka J; Holubec L; Pesta M; Topolcan O; Hora M; Eret V; Finek J; Chottova-Dvorakova M; Babjuk M; Novak K; Stolz J
Anticancer Res; 2010 Feb; 30(2):665-70. PubMed ID: 20332487
[TBL] [Abstract][Full Text] [Related]
4. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
[TBL] [Abstract][Full Text] [Related]
5. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
[TBL] [Abstract][Full Text] [Related]
6. DD3(PCA3) gene expression in cancer and prostatic hyperplasia.
Floriano-Sánchez E; Cárdenas-Rodríguez N; Castro-Marín M; Alvarez-Grave P; Lara-Padilla E
Clin Invest Med; 2009 Dec; 32(6):E258. PubMed ID: 20003831
[TBL] [Abstract][Full Text] [Related]
7. Molecular Diagnostic of Prostate Cancer From Body Fluids Using Methylation-Specific PCR (MS-PCR) Method.
Minciu R; Dumache R; Gheorghe P; Daminescu L; Rogobete AF; Ionescu D
Clin Lab; 2016; 62(6):1183-6. PubMed ID: 27468582
[TBL] [Abstract][Full Text] [Related]
8. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis.
Robert G; Jannink S; Smit F; Aalders T; Hessels D; Cremers R; Mulders PF; Schalken JA
Prostate; 2013 Jan; 73(2):113-20. PubMed ID: 22674214
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic potential in prostate cancer of a panel of urinary molecular tumor markers.
Talesa VN; Antognelli C; Del Buono C; Stracci F; Serva MR; Cottini E; Mearini E
Cancer Biomark; 2009; 5(6):241-51. PubMed ID: 20037200
[TBL] [Abstract][Full Text] [Related]
10. Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis.
Neves AF; Araújo TG; Biase WK; Meola J; Alcântara TM; Freitas DG; Goulart LR
Clin Biochem; 2008 Oct; 41(14-15):1191-8. PubMed ID: 18640109
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiles in prostate cancer: identification of candidate non-invasive diagnostic markers.
Mengual L; Ars E; Lozano JJ; Burset M; Izquierdo L; Ingelmo-Torres M; Gaya JM; Algaba F; Villavicencio H; Ribal MJ; Alcaraz A
Actas Urol Esp; 2014 Apr; 38(3):143-9. PubMed ID: 24206626
[TBL] [Abstract][Full Text] [Related]
12. Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions.
Schostak M; Miller K; Krause H; Schrader M; Kempkensteffen C; Kollermann J
Cancer Detect Prev; 2006; 30(5):449-54. PubMed ID: 17067752
[TBL] [Abstract][Full Text] [Related]
13. Overexpressed Rce1 is positively correlated with tumor progression and predicts poor prognosis in prostate cancer.
Huang L; Li M; Wang D; He J; Wu W; Zeng Q; Li J; Xiao M; Hu J; He Y; Li Y; Mai L; Liu W
Hum Pathol; 2016 Jan; 47(1):109-14. PubMed ID: 26546252
[TBL] [Abstract][Full Text] [Related]
14. Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer.
Guzel E; Karatas OF; Semercioz A; Ekici S; Aykan S; Yentur S; Creighton CJ; Ittmann M; Ozen M
Int J Cancer; 2015 Feb; 136(4):875-9. PubMed ID: 24976077
[TBL] [Abstract][Full Text] [Related]
15. The combination of urine DD3(PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer.
Mearini E; Antognelli C; Del Buono C; Cochetti G; Giannantoni A; Nardelli E; Talesa VN
Biomarkers; 2009 Jun; 14(4):235-43. PubMed ID: 19489685
[TBL] [Abstract][Full Text] [Related]
16. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
17. [Quantitative detection of DD3 mRNA in prostate cancer tissues by real-time fluorescent quantitative reverse transcription polymerase chain reaction].
Tao ZH; Mao XL; Wang CH; Chen XD; Yu KY; Weng ZL; Hu YP; Zhang XH; Xie H; Wang OC; Song QT; Li CD; Chen ZG
Zhonghua Nan Ke Xue; 2007 Feb; 13(2):130-3. PubMed ID: 17345768
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of Pleomorphic Adenoma Gene-Like 2 Is a Novel Poor Prognostic Marker of Prostate Cancer.
Guo J; Wang M; Wang Z; Liu X
PLoS One; 2016; 11(8):e0158667. PubMed ID: 27537362
[TBL] [Abstract][Full Text] [Related]
19. Urinary Nucleic Acid TSPAN13-to-S100A9 Ratio as a Diagnostic Marker in Prostate Cancer.
Yan C; Kim YH; Kang HW; Seo SP; Jeong P; Lee IS; Kim D; Kim JM; Choi YH; Moon SK; Yun SJ; Kim WJ
J Korean Med Sci; 2015 Dec; 30(12):1784-92. PubMed ID: 26713053
[TBL] [Abstract][Full Text] [Related]
20. Expression analysis of delta-catenin and prostate-specific membrane antigen: their potential as diagnostic markers for prostate cancer.
Burger MJ; Tebay MA; Keith PA; Samaratunga HM; Clements J; Lavin MF; Gardiner RA
Int J Cancer; 2002 Jul; 100(2):228-37. PubMed ID: 12115574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]